Overview

Evaluation of the Achievement of a Pharmacodynamic Target of Piperacillin-Tazobactam for the Population With Obesity

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-19
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the feasibility of an open randomized controlled study which would assess the proportion patients with obesity who will have a favorable pharmacodynamic parameter (i.e. fT\> 100% MIC) after 24 hours of piperacillin-tazobactam administered as a prolonged intermittent infusion compared to a standard infusion.
Phase:
PHASE4
Details
Lead Sponsor:
CR-CSSS Champlain-Charles-Le Moyne